Multiple threat actors, both state-sponsored and financially motivated, are exploiting the CVE-2025-8088 high-severity vulnerability in WinRAR for initial access and to deliver various malicious ...

Investors might want to bet on Cartesian Therapeutics, Inc. (RNAC), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...

IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential opportunity for a single pivotal trial expected to commence in 1H26 Phase 1/2 ...

Cartesian Growth Corp. III Class A ( (CGCT)) just unveiled an announcement. On December 17, 2025, Cartesian Growth Corporation III and Factorial Inc. signed a definitive business combination agreement ...

Is it beginning to look a lot like Christmas? I grew up measuring Christmas by the tree. Cut-your-own, grocery-lot deals, even in my young adult years, Manhattan bodega carry-aways à la “When Harry ...

Given two integer arrays inorder and postorder where inorder is the inorder traversal of a binary tree and postorder is the postorder traversal of the same tree, construct and return the binary tree.

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases, eliminating the need for preconditioning chemotherapy. Lead candidate Descartes-08 showed promising ...

Check out the Rift Traversal Extraction Mode Cinematic Trailer for Naraka: Bladepoint, an online multiplayer battle royale game developed by 24 Entertainment. Players can participate in a new ...

Traversal Inc., a startup building an artificial intelligence platform focused on site reliability engineering and observability, today announced its launch with $48 million in funding. The funds were ...

They met at 10 p.m. each weeknight, after class at Columbia University. Sometimes talking over Zoom until 2 AM, Anish Agarwal, Raaz Dwivedi, Ahmed Lone, and Raj Agrawal talked about what it might mean ...

Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis (MG ...